Since the beginning of the 50s of the last century, numerous classifications of sarcoidosis have been proposed, which to one degree or another satisfied specialists at certain stages of the development of medical technologies. Currently, sarcoidosis of the respiratory system is divided into five stages (from 0 to IV) based on the results of chest Xray examination. Active introduction into clinical practice of computed tomography and its more advanced version – lowdose multislice computed tomography (MSCT) – allows to carry out an effective diagnosis of sarcoidosis, including in outpatient practice, as well as when performing active screening and dynamic monitoring of the course of the disease. On the basis of the studies which were carried out, the dissonance between the progress in technology (from X-ray pattern to MSCT) and the stagnation of the conceptual issues of the classification of sarcoidosis is discussed, which urgently requires its reforming. Firstly, the category of patients with concomitant lesions of the intrathoracic lymph nodes (ITLN) and parenchyma (stage II) has sharply increased, which reflects the increased technological level of radiological diagnostics. As a result, the percentage of stages with isolated lymph node involvement (stage I) and isolated dissemination of the parenchyma (stage III) decreased. The classification based on MSCT data allows to more accurately determine the severity of the disease. This is of therapeutic and prognostic importance, since most patients of stage I generally do not need treatment, while symptomatic stage II requires hormone therapy. One should also take into account the possibility of spontaneous remission, which is observed more often in stage I. The main conclusion is that at present day the principle of staging in the classification of sarcoidosis can no longer satisfy the realities of modern clinics. It is more correct to single out the clinical and radiological forms of sarcoidosis: sarcoidosis of the ITLN, sarcoidosis of the ITLN and lungs, sarcoidosis of the lungs, as well as sarcoidosis of the respiratory system, combined with a single lesion of other organs.

No abstract

No abstract

Контактная информацияАнатолий Васильевич Леншин, д-р мед. наук, профессор, ведущий научный сотрудник лаборатории функциональных методов исследования дыхательной системы, Федеральное государственное бюджетное научное учреждение «Дальневосточный научный центр физиологии и патологии дыхания», 675000, Россия, г. Благовещенск, ул. Калинина, 22.

The word sarcoidosis comes from the Greek word “sarcoid”, meaning “having flesh or tissue”, and the Greek suffix “-osis”, meaning “condition”, referring to skin lesions on various parts of the body. Over the course of history, sarcoidosis has been consistently dealt with by physicians of various specialties. The palm of victory belongs to dermatologists, and further for quite a long period of time, phthisiatricians dealt with this problem, then pulmonologists, and, more recently, doctors of many other specialties. The term “Besnier-Boeck-Schaumann disease” was officially approved at the congress of dermatologists in Strasbourg in 1934. This name of the disease has been preserved to the present for a little less than 90 years. However, it should be noted that in recent years their names in the headlines and texts of articles are mentioned much less frequently. To our knowledge in the PubMed information registry, only one paper was published in 2022 on various clinical and experimental studies of sarcoidosis, which mentions the name of the disease as “BesnierBoeck-Schaumann disease”. For illustration, several presentations of own clinical and radiological observations are given, identical in their pathogenetic parameters, noticed and described for the first time by Besnier, Boeck, Schaumann and Löfgren. These presentations are formed using modern diagnostic technologies, which significantly expand the visualization possibilities of sarcoidosis variants and fully reveal the fullness of the symptom complexes that were noticed and described by the path-breakers of sarcoidosis.